Adaptive Biotechnologies (ADPT) Common Equity (2018 - 2026)

Adaptive Biotechnologies has disclosed Common Equity across 9 years of filings, most recently posting $216.3 million for Q1 2026.

• Common Equity for Q1 2026 came in at $216.3 million, up 13.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $216.3 million (up 13.73% YoY), and the FY2025 annual result was $218.8 million, up 8.05% from the prior year.
• Common Equity came in at $216.3 million for Q1 2026 at Adaptive Biotechnologies, down from $218.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $553.3 million in Q1 2022 to a low of $179.5 million in Q2 2025.
• The 5-year median for Common Equity is $274.8 million (2024), against an average of $321.5 million.
• Across the five-year window, Common Equity slumped 39.03% in 2024 and rose 13.73% in 2026, its largest moves.
• Adaptive Biotechnologies' Common Equity stood at $464.1 million in 2022, then slumped by 33.57% to $308.3 million in 2023, then sank by 34.32% to $202.5 million in 2024, then rose by 8.05% to $218.8 million in 2025, then dropped by 1.12% to $216.3 million in 2026.
• The last three Common Equity figures came in at $216.3 million (Q1 2026), $218.8 million (Q4 2025), and $204.3 million (Q3 2025), per Business Quant data.